Osteosarcoma - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Osteosarcoma - Pipeline Review, H2 2016

Osteosarcoma - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Osteosarcoma - Pipeline Review, H2 2016
Published Aug 17, 2016
223 pages — Published Aug 17, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Osteosarcoma - Pipeline Review, H2 2016, provides an overview of the Osteosarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Osteosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Osteosarcoma
- The report reviews pipeline therapeutics for Osteosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Osteosarcoma therapeutics and enlists all their major and minor projects
- The report assesses Osteosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Osteosarcoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Osteosarcoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Osteosarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing

  
Source:
Document ID
GMDHC8358IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents28
  List of Tables81
  List of Figures91
Introduction101
  Global Markets Direct Report Coverage101
Osteosarcoma Overview111
Therapeutics Development122
  Pipeline Products for Osteosarcoma Overview121
  Pipeline Products for Osteosarcoma Comparative Analysis131
Osteosarcoma Therapeutics under Development by Companies142
Osteosarcoma Therapeutics under Investigation by Universities/Institutes161
Osteosarcoma Pipeline Products Glance172
  Clinical Stage Products171
  Early Stage Products181
Osteosarcoma Products under Development by Companies191
Osteosarcoma Products under Investigation by Universities/Institutes201
Osteosarcoma Companies Involved in Therapeutics Development2120
  Advaxis, Inc.211
  Amgen Inc.221
  AVEO Pharmaceuticals, Inc.231
  Bayer AG241
  Bellicum Pharmaceuticals, Inc.251
  Celldex Therapeutics, Inc.261
  CytRx Corporation271
  Eleison Pharmaceuticals LLC281
  Exelixis, Inc.291
  Isofol Medical AB301
  MediaPharma s.r.l.311
  Merck &Co., Inc.321
  Merrimack Pharmaceuticals, Inc.331
  Netris Pharma S.A.S.341
  Novartis AG351
  Oncolys BioPharma Inc361
  Pfizer Inc.371
  Shionogi &Co., Ltd.381
  Teijin Pharma Limited391
  United Therapeutics Corporation401
Osteosarcoma Therapeutics Assessment4111
  Assessment by Monotherapy Products411
  Assessment by Target423
  Assessment by Mechanism of Action453
  Assessment by Route of Administration482
  Assessment by Molecule Type502
Drug Profiles52158
  3D-QM Drug Profile521
  3D-QMS Drug Profile531
  ADXS-HER2 Drug Profile544
  aldoxorubicin hydrochloride Drug Profile5815
  AM-7209 Drug Profile731
  AU-101 Drug Profile741
  AV-203 Drug Profile753
  axitinib Drug Profile786
  cabozantinib s-malate Drug Profile8418
  Cellular Immunotherapy for GD2 Expressing Solid Tumors Drug Profile1022
  Cellular Immunotherapy to Target HER2 for Glioblastoma Multiforme and Osteosarcoma Drug Profile1041
  Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology Drug Profile1051
  celyvir Drug Profile1061
  CGS-200 Drug Profile1071
  cisplatin SR Drug Profile1082
  dihydroartemisinin Drug Profile1101
  dinutuximab Drug Profile1112
  everolimus Drug Profile11312
  glembatumumab vedotin Drug Profile1255
  irinotecan hydrochloride Drug Profile13011
  ligerin Drug Profile1411
  LLL-12 Drug Profile1421
  Modufolin Drug Profile1432
  Monoclonal Antibody for Osteosarcoma Drug Profile1451
  Monoclonal Antibody to Inhibit GD2 for Oncology Drug Profile1461
  Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastoma and Osteosarcoma Drug Profile1472
  MPE-8.3 Drug Profile1491
  NP-137 Drug Profile1501
  OBP-702 Drug Profile1511
  Oligonucleotides to Inhibit Thymidylate Synthase and Dihydrofolate Reductase for Osteosarcoma and Colon Cancer Drug Profile1521
  pazopanib hydrochloride Drug Profile1537
  pembrolizumab Drug Profile16031
  Peptide to Target COX-2 and MAS-GPCR for Oncology Drug Profile1912
  radium Ra 223 dichloride Drug Profile1939
  RSF-101 Drug Profile2021
  S-588410 Drug Profile2032
  SEN-461 Drug Profile2051
  Small Molecules to Agonize Vitamin D3 Receptor for Osteosarcoma Drug Profile2061
  Small Molecules to Inhibit CaMKII for Osteosarcoma Drug Profile2071
  T-2GES Drug Profile2081
  Vaccine for Osteosarcoma Drug Profile2091
Osteosarcoma Dormant Projects2102
Osteosarcoma Discontinued Products2121
Osteosarcoma Product Development Milestones2139
  Featured News &Press Releases2131
    Apr 28, 2016: FDA Grants Advaxis Fast Track Designation for ADXS-HER2 for Patients with Newly-Diagnosed, Non-Metastatic, Surgically-Resectable Osteosarcoma2131
    Apr 20, 2016: Celldex Therapeutics Presents Data Supporting the Clinical Development of Glembatumumab Vedotin at the AACR Annual Meeting 20162131
    Apr 13, 2016: Sarcoma Foundation of America Honors Advaxis for Advancements in Immunotherapy Platform2141
    Mar 23, 2016: Advaxis Hosts Research Reception to Review Late-Breaking ADXS-HER2 at AACR Abstract2151
    Mar 21, 2016: Survival Results with Advaxis HER2 Targeted Immunotherapy in Canine Osteosarcoma Published in Clinical Cancer Research2151
    Mar 16, 2016: Merrimack to Present on ONIVYDE (irinotecan liposome injection) at the 2016 American Association for Cancer Research Annual Meeting2161
    Jan 19, 2016: Advaxis Expands Intellectual Property for Lm Technology Platform2161
    Dec 01, 2015: Advaxis Receives Orphan Drug Designation in the European Union for ADXS-HER2 for the Treatment of Osteosarcoma2171
    Nov 30, 2015: CapGenesis Files Five Orphan Drug Designation Requests with the FDA and EMA for CGS-200 as a Topical Analgesic2171
    Jul 21, 2015: Advaxis Expands Intellectual Property for Lm Technology Platform in HER22181
    May 04, 2015: CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers2191
    May 01, 2015: Eleison Announces Successful Completion of Stage 1 of its Phase II Trial of ILC (Inhaled Lipid-complexed Cisplatin) for Pediatric Bone Cancer2201
    Apr 28, 2015: Advaxis Enhances Lm-LLO Cancer Immunotherapy Intellectual Property With USPTO Patent Addressing ADXS-HER22201
    Nov 04, 2014: Advaxis to Present Data of ADXS-cHER2 at the Society for Immunotherapy of Cancer 29th Annual Meeting2211
Appendix2222
  Methodology2221
  Coverage2221
  Secondary Research2221
  Primary Research2221
  Expert Panel Validation2221
  Contact Us2221
  Disclaimer2231

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Osteosarcoma - Pipeline Review, H2 2016" Aug 17, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Osteosarcoma-Pipeline-Review-H2-2016-2088-16385>
  
APA:
Global Markets Direct - Market Research. (2016). Osteosarcoma - Pipeline Review, H2 2016 Aug 17, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Osteosarcoma-Pipeline-Review-H2-2016-2088-16385>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.